“We are having a wealth of new medications that are helping our patients. Primarily with advanced disease, but…maybe there are going to be some applications to move that earlier and earlier in the in the disease process,” says Christopher B. Anderson, MD, MPH.
In this video Chad R. Ritch, MD, MBA, FACS, and Christopher B. Anderson, MD, MPH,discuss the newest innovations in the bladder cancer space in terms of treatments and risk stratification techniques. This discussion is part of a larger forum on bladder cancer with Sam S. Chang, MD, MBA. Chang is a Patricia and Rodes Hart professor of urology and oncology at the Vanderbilt University Medical Center and chief surgical officer at the Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee. Ritch is an associate professor of urology and an associate director of UHealth International at the Miller School of Medicine, University of Miami, Florida. Anderson is an assistant professor of urology at Columbia University Irving Medical Center, Columbia University, New York City, New York.